GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
-35
c/trialwatch·posted 1 year ago by u/adaeze_weiss

[Meta] the FLOW rule is doing its job and people should stop complaining

Readout

the FLOW rule is doing its job and people should stop complaining. This affects how posts get sorted and removed, so it belongs in the open.

The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table.

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.

270 up / 305 down47% upvoted11 commentsid zhtdp815 Oct 2024

11 comments

11 in this archive, depth 3

best — the order this archive was captured in

u/anders_karlsen8 points·1 year ago

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

replysharereportpermalink
u/plateau_patrol2 points·1 year ago

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

replysharereportpermalink
u/forest_plot_fionaMOD6 points·1 year ago

Retitled: the original quoted a diabetes endpoint as an obesity result.

replysharereportpermalink
u/emil_agyeman7 points·1 year ago·edited

Retitled: the original quoted a diabetes endpoint as an obesity result.

This is the distinction that would end about half the arguments on this board.

replysharereportpermalink
u/hugo_bergstrom5 points·1 year ago

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

replysharereportpermalink
u/milos_vanhecke4 points·1 year ago

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

replysharereportpermalink
u/heart_rate_bump2 points·1 year ago

open-label extensions are not the same evidence as the randomised phase

replysharereportpermalink
u/enzo_ferrari3 points·1 year ago

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

replysharereportpermalink
u/niels_norgaard2 points·1 year ago

That is the 68-week readout, not the 72-week one. Different trial, different duration.

replysharereportpermalink
u/adaeze_weissOP1 point·1 year ago·edited

That is the 68-week readout, not the 72-week one.

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

replysharereportpermalink
u/adaeze_weissOP1 point·1 year ago

Which trial, and which arm?

replysharereportpermalink
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.